Multicenter, USA - 30 Jan `16Incyte: Topical Ruxolitinib for the Treatment of Vitiligo

Official Title: Topical Ruxolitinib for the Treatment of Vitiligo

In Brief: The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.

Description: The hypothesis is that JAK inhibitors can also successfully treat vitiligo. Lesional skin of both alopecia areata and vitiligo primarily contain T cells in a TH1 response as opposed to a mixed cell infiltrate such as in psoriasis or lichen planus. Both alopecia areata and vitiligo are TH1 mediated diseases dependent on the production of IFN-gamma to drive the response. CD8+ T cells are both necessary and sufficient for melanocyte destruction in vitiligo (van den Boorn JG et al 2009) and CD8+NKG2D+ T cells are also necessary and sufficient for hair loss in alopecia areata (Gilhar A et al 2013).

Ages Eligible: 18 Years and older

Start Date: January 2016

Completion Date (estimated): February 2017

Status: Completed

Study ID from ClinicalTrials.gov: NCT02809976 
Other Study ID Numbers: I-18424-15-06 

Location: multicenter, USA

Contact: To learn more about this study, you or your doctor may contact David Rosmarin, MD at Tufts Medical Center. Please refer to this study by its NCT number.

FAQOther Questions

  • How long does it take to treat vitiligo?

    Treatment results will vary by person and type of vitiligo. The rule of thumb is that you will need to allow at least 3 to 6 months before you begin to see results from any trea...

  • Can a gluten-free diet help with vitiligo?

    It's very unlikely. We have specifically looked into claims that gluten-free diet may ease symptoms of vitiligo, or completely reverse it, and found no firm scientific evidence ...

  • Is vitiligo contagious?

    Vitiligo is NOT contagious. It cannot be passed on or caught from touching someone with vitiligo, shaking hands, swimming in the same pool, sharing towels, sitting next to someo...